ProText Mobility, Inc. (TXTM) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 58.00 means the share price is 58.00 times one year of earnings per share. Market cap $11.3M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerProText Mobility, Inc. (TXTM) trades at $0.0058. ProText Mobility, Inc. is a biotech company focused on developing pharmaceutical botanical medicines formulated with highly bioavailable plant extracts. Market cap: $11.3M, Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for TXTM: TXTM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
ProText Mobility, Inc. (TXTM) Healthcare & Pipeline Overview
ProText Mobility, Inc. is a biotechnology firm specializing in pharmaceutical botanical medicines, utilizing highly bioavailable plant extracts. As a subsidiary of Plandaí Biotechnology, Inc., the company operates within the competitive healthcare sector, focusing on developing innovative botanical treatments. With a small team, TXTM is navigating the complex regulatory landscape of pharmaceutical development.
What Is the Investment Thesis for TXTM?
Investing in ProText Mobility, Inc. presents a high-risk, high-reward scenario given its early stage and focus on pharmaceutical botanical medicines. The company's value hinges on the successful development and commercialization of its plant-extract-based drugs. Key value drivers include the potential for breakthrough treatments derived from its proprietary formulations and the ability to secure regulatory approvals. Growth catalysts include advancing its drug pipeline through clinical trials and establishing partnerships with larger pharmaceutical companies. However, potential investors must consider the risks associated with biotech investments, including regulatory hurdles, clinical trial failures, and the need for substantial capital. With a negative P/E ratio of -2218.93 and a volatile beta of -3.13, TXTM's financial metrics reflect its speculative nature. The company's success depends on its ability to navigate these challenges and deliver on its promise of innovative botanical medicines.
Based on FMP financials and quantitative analysis
TXTM Key Highlights
Market capitalization of $11.3M indicates a micro-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -2218.93 reflects the company's current lack of profitability, typical for early-stage biotech firms investing heavily in research and development.
- Beta of -3.13 suggests the stock price moves inversely and more drastically than the market, indicating high volatility.
- The company's focus on highly bioavailable plant extracts aims to improve drug absorption and effectiveness, a key differentiator in the pharmaceutical sector.
- Operating as a subsidiary of Plandaí Biotechnology, Inc. provides ProText Mobility with access to resources and expertise in botanical research.
Who Are TXTM's Competitors?
TXTM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| BETRF BetterLife Pharma Inc. | $0.19 | -4.88% | $30.9M | — |
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 79 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 69 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TXTM's Key Strengths?
Focus on pharmaceutical botanical medicines.
- Formulations with highly bioavailable plant extracts.
- Potential for novel treatments with natural benefits.
- Subsidiary of Plandaí Biotechnology, Inc.
What Are TXTM's Weaknesses?
Early-stage company with limited resources.
- Dependence on parent company for support.
- Lack of established revenue stream.
- Small team with only one employee.
What Are the Key Risks for TXTM?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Rich valuation — a P/E of 58.00 runs well above the Healthcare sector’s ~21.10x, leaving little room for a miss.
- Regulatory hurdles and clinical trial failures could delay or prevent commercialization.
- Competition from established pharmaceutical companies with greater resources.
- Need for substantial capital to fund research and development.
- Market acceptance of botanical medicines may be limited.
- OTC Other listing indicates higher risk and lower transparency.
What Are TXTM's Competitive Advantages?
- Proprietary formulations and extraction methods for botanical medicines.
- Patent protection for its intellectual property.
- Focus on highly bioavailable plant extracts.
- Expertise in botanical research and development.
What Does TXTM Do?
ProText Mobility, Inc. is a biotechnology company dedicated to the development of pharmaceutical botanical medicines. These medicines are distinguished by their formulation with highly bioavailable plant extracts, aiming to enhance therapeutic efficacy and patient outcomes. The company operates as a subsidiary of Plandaí Biotechnology, Inc., leveraging its parent company's resources and expertise in the botanical space. Based in Boca Raton, Florida, ProText Mobility is focused on innovating within the pharmaceutical sector by harnessing the potential of plant-derived compounds. The company's approach involves rigorous scientific research and development to create medicines that meet pharmaceutical standards while utilizing the natural benefits of botanical extracts. Their strategic focus on bioavailability is intended to improve drug absorption and effectiveness, addressing a key challenge in pharmaceutical development. ProText Mobility's business model centers around the discovery, development, and potential commercialization of these botanical medicines. While specific details on their product pipeline are not available, the company's mission is to create novel treatments that can address unmet medical needs. As a small entity with one employee, the company faces the challenges of resource constraints typical of early-stage biotech firms, requiring strategic partnerships and efficient resource allocation to advance its research and development efforts.
What Products and Services Does TXTM Offer?
- Develop pharmaceutical botanical medicines.
- Formulate medicines with highly bioavailable plant extracts.
- Conduct research and development to create novel treatments.
- Aim to improve drug absorption and effectiveness.
- Focus on innovating within the pharmaceutical sector.
- Harness the potential of plant-derived compounds.
- Seek to address unmet medical needs with botanical solutions.
How Does TXTM Make Money?
- Discovery and development of pharmaceutical botanical medicines.
- Securing patents for proprietary formulations and extraction methods.
- Potential commercialization of approved drugs through partnerships or direct sales.
- Generating revenue through licensing agreements and royalties.
What Industry Does TXTM Operate In?
ProText Mobility, Inc. operates within the biotechnology sector, a dynamic and competitive industry characterized by rapid innovation and high regulatory scrutiny. The market for botanical medicines is growing, driven by increasing consumer interest in natural and alternative therapies. However, the company faces competition from established pharmaceutical giants and other biotech firms developing novel treatments. The industry is characterized by high R&D costs, long development timelines, and a high failure rate for clinical trials. Success depends on securing patents, navigating regulatory approvals, and demonstrating clinical efficacy.
Who Are TXTM's Key Customers?
- Pharmaceutical companies seeking novel drug candidates.
- Patients in need of effective and natural treatments.
- Healthcare providers looking for innovative therapeutic options.
- Potential partners for drug development and commercialization.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
How ProText Mobility, Inc. Is Valued
ProText Mobility, Inc. carries a market capitalization of $11.3M, placing it in the micro-cap category.
Company Profile
ProText Mobility, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Fort Lauderdale, US. TXTM has traded publicly since 2003.
Key Financial Metrics
TXTM trades at a trailing price-to-earnings ratio of 58.00, above the Healthcare sector average of ~21.10x. Its earnings yield is 1.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
ProText Mobility, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 11.31 places it in the safe zone, indicating low near-term bankruptcy risk.
Insider Activity
12 transactions · 8 purchases, 0 sales, 4 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
TXTM Financials
TXTM Latest News
No recent news available for TXTM.
TXTM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for TXTM.
Price Targets
Wall Street price target analysis for TXTM.
TXTM MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for TXTM; grades run from A+ (80-100) to F (below 30).
Leadership: Dylon Du Plooy
Unknown
Information on Dylon Du Plooy's professional background is limited. As the leader of ProText Mobility, Inc., a biotech company focused on developing pharmaceutical botanical medicines, Du Plooy's expertise likely encompasses areas such as pharmaceutical development, botanical science, and business strategy. Given the company's focus on plant extracts and bioavailability, Du Plooy may possess specialized knowledge in these areas. His role involves overseeing the company's research and development efforts, managing its limited resources, and seeking opportunities for growth and partnerships.
Track Record: Due to limited information, Dylon Du Plooy's track record at ProText Mobility, Inc. is not fully available. As the head of a small biotech company, his key responsibilities would include guiding the company's strategic direction, securing funding, and advancing its drug pipeline. Successes would be measured by milestones such as successful clinical trials, patent approvals, and strategic partnerships. However, specific achievements and milestones under his leadership are not currently known.
TXTM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that ProText Mobility, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial disclosures. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ. This tier is generally for highly speculative or distressed companies.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume can lead to price manipulation and volatility.
- Higher risk of fraud or mismanagement compared to listed companies.
- OTC Other status indicates potential financial instability or regulatory non-compliance.
- Potential delisting or difficulty in uplisting to a higher exchange.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the company's capital structure and funding needs.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Subsidiary of Plandaí Biotechnology, Inc. may provide some level of oversight.
- Focus on developing pharmaceutical botanical medicines suggests a scientific approach.
- Company has been in operation for several years.
- Presence of a CEO, Dylon Du Plooy, indicates leadership structure.
ProText Mobility, Inc. Healthcare Stock: Key Questions Answered
What are the main risks for TXTM?
Investing in TXTM carries substantial risks inherent to its early-stage biotech nature and OTC listing. Key risks include regulatory hurdles and the potential for clinical trial failures, which could significantly impact its drug development pipeline.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on the company due to its OTC listing and small market capitalization.
- Financial data is limited and may not be fully up-to-date.